Please check your internet connection and try again.
# Ecospirin (Aspirin Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with antiplatelet, analgesic, and antipyretic properties. The enteric coating is designed to reduce gastrointestinal irritation by delaying the release of aspirin until it reaches the small intestine.
## Primary Indications
* **Cardiovascular risk reduction:** Prevention of myocardial infarction and stroke in patients with established cardiovascular disease or at high risk.
* **Pain and fever:** Relief of mild to moderate pain and reduction of fever.
* **Inflammation:** Management of inflammatory conditions (less common for enteric-coated formulations due to slower onset of action compared to non-coated forms).
## Adult Dosing
Dosing is highly dependent on the indication.
* **Cardiovascular prophylaxis:**
* **Secondary prevention:** 75-100 mg once daily.
* **Primary prevention:** 75-100 mg once daily (decision based on individual risk assessment). Some guidelines may suggest higher doses initially, but long-term use is typically at lower doses.
* **Pain and fever:** 325-650 mg every 4-6 hours as needed. Maximum daily dose typically 4000 mg.
* **Inflammatory conditions:** Higher doses may be used, but typically not with enteric-coated formulations due to slow absorption. If used, doses can range from 2.4g to 4g daily divided into multiple doses.
## Pediatric Dosing
Aspirin is generally **not recommended** in children and adolescents (<19 years) for fever or viral illnesses due to the risk of Reye's syndrome. Specific indications for aspirin in pediatrics (e.g., Kawasaki disease) should be guided by specialist recommendations and available literature, often involving higher doses with careful monitoring. Dosing for Kawasaki disease can vary, but initial doses might be 80-100 mg/kg/day in four divided doses, followed by a lower dose (3-5 mg/kg/day) for several weeks to months.
## Dose Adjustments
* **Renal impairment:** Use with caution. Lower doses may be considered, especially in severe impairment.
* **Hepatic impairment:** Use with caution. Monitor for signs of liver toxicity.
* **Elderly:** Increased risk of gastrointestinal bleeding and other adverse effects. Use lowest effective dose and consider alternatives if possible.
## Contraindications
* Hypersensitivity to aspirin, salicylates, NSAIDs, or any component of the formulation.
* Active peptic ulcer disease or history of recurrent ulcers.
* Gastrointestinal bleeding.
* Severe hepatic or renal impairment.
* Severe heart failure.
* Children and adolescents with viral infections (due to risk of Reye's syndrome).
* Bleeding disorders (e.g., hemophilia).
* Last trimester of pregnancy.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, vomiting, abdominal pain, occult bleeding, frank gastrointestinal bleeding, ulceration.
* **Hematologic:** Increased bleeding time, bruising, petechiae, epistaxis.
* **Hypersensitivity:** Bronchospasm (especially in aspirin-sensitive asthmatics), urticaria, angioedema.
* **Renal:** Acute kidney injury, interstitial nephritis.
* **Hepatic:** Elevated liver enzymes.
* **Other:** Tinnitus (especially at higher doses), dizziness, confusion.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding. Concurrent use requires careful consideration and monitoring.
* **Other NSAIDs and COX-2 inhibitors:** Additive risk of gastrointestinal toxicity and bleeding.
* **Corticosteroids:** Increased risk of gastrointestinal ulceration and bleeding.
* **Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs):** Increased risk of gastrointestinal bleeding.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, diuretics):** NSAIDs can reduce antihypertensive efficacy and increase risk of renal dysfunction.
* **Methotrexate:** Aspirin can decrease methotrexate clearance, increasing toxicity.
* **Valproic acid:** Aspirin can displace valproic acid from protein-binding sites, increasing free valproic acid levels.
* **Uricosuric agents (e.g., probenecid):** Aspirin can inhibit the uricosuric effect.
* **Alcohol:** Increased risk of gastrointestinal irritation and bleeding.
## Monitoring
* **Signs and symptoms of gastrointestinal bleeding:** Melena, hematemesis, abdominal pain.
* **Signs and symptoms of bleeding elsewhere:** Easy bruising, prolonged bleeding from cuts, epistaxis.
* **Renal function:** Serum creatinine, BUN, especially in patients with risk factors.
* **Liver function:** LFTs, especially with chronic use or high doses.
* **Tinnitus:** Can be an early sign of salicylism, particularly at higher doses.
## Clinical Pearls
* The enteric coating helps protect the stomach lining but does not eliminate the risk of gastrointestinal bleeding or ulceration, especially with long-term use or in high-risk individuals.
* For urgent antiplatelet effects, non-coated aspirin is preferred due to faster absorption.
* Avoid concomitant use with other NSAIDs unless specifically indicated and closely monitored.
* Discontinue aspirin at least 5-7 days before elective surgery or procedures where bleeding is a concern, in consultation with the surgeon.
* In patients with a history of gastrointestinal bleeding or ulcers, consider co-administration of a proton pump inhibitor (PPI) or misoprostol.
***
*This information is intended for healthcare professionals. Always consult the current prescribing information and relevant clinical guidelines before making any treatment decisions.*
